Evidence map›Paper›PMID 29204333›Full record

ArticleCurrent epidemiology reports2017

Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.

John G Connolly, Shirley V Wang, Candace C Fuller, Sengwee Toh, Catherine A Panozzo, Noelle Cocoros, Meijia Zhou, Joshua J Gagne, Judith C Maro

Abstract read
In one paragraph

Article in Current epidemiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

John G ConnollyDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA.
Shirley V WangDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA.
Candace C FullerDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.
Sengwee TohDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.
Catherine A PanozzoDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.
Noelle CocorosDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.
Meijia ZhouCenter for Clinical Epidemiology and Biostatistics, Pereleman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Joshua J GagneDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA.
Judith C MaroDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USHarvard Pilgrim Health Care · USUniversity of Pennsylvania · US

Funding

Privacy-protecting distributed analysis of biomedical big dataU01EB023683 · NIBIB · HARVARD PILGRIM HEALTH CARE, INC. · PI TOH, DARREN · 2016 to 2018
$1.4M
FDA HHS HHSF223200910006INIBIB NIH HHS U01 EB023683
6 · The paper itself

Abstract

purpose of reviewAn important component of the Food and Drug Administration's Sentinel Initiative is the active post-market risk identification and analysis (ARIA) system, which utilizes semi-automated, parameterized computer programs to implement propensity-score adjusted and self-controlled risk interval designs to conduct targeted surveillance of medical products in the Sentinel Distributed Database. In this manuscript, we review literature relevant to the development of these programs and describe their application within the Sentinel Initiative. RECENT

findingsThese quality-checked and publicly available tools have been successfully used to conduct rapid, replicable, and targeted safety analyses of several medical products. In addition to speed and reproducibility, use of semi-automated tools allows investigators to focus on decisions regarding key methodological parameters. We also identified challenges associated with the use of these methods in distributed and prospective datasets like the Sentinel Distributed Database, namely uncertainty regarding the optimal approach to estimating propensity scores in dynamic data among data partners of heterogeneous size. SUMMARY: Future research should focus on the methodological challenges raised by these applications as well as developing new modular programs for targeted surveillance of medical products.

Indexed as

ARIAdrug safetypharmacoepidemiologySentinelsurveillancetargeted

Identifiers

PMID29204333
PMCPMC5710750
OpenAlexW2762621503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.